Patients needing language assistance had lower PACU opioid consumption (median 5 vs 10 MEDD, p=0.021) after matching

Description #

In the propensity-score-matched cohort (295 per group), patients who needed language assistance services (LAS) had significantly lower opioid consumption in the post-anesthesia care unit (PACU) than patients who did not need LAS: median morphine-equivalent daily dose (MEDD) of 5 (IQR 5–10) vs 10 (IQR 5–15); p = 0.021 (Table 2). (In the unmatched pre-matching cohort the same comparison was 5 vs 5, p = 0.067, i.e., not significant.)

"Patients who needed LAS had significantly lower opioid consumption (median: 5 vs. 10; p = 0.021) and reported lower pain intensity during PACU stay (median: 2.3 vs. 2.6; p = 0.046) than subjects not requiring language translation." (Kapoor, 2023, p. 5)

Methods Context #

What? #ⓘ

The observable: opioid consumption in the PACU, recorded as morphine-equivalent daily dose (MEDD), a secondary endpoint.

"Secondary endpoints included opioid use in PACU and the use of regional analgesia." (Kapoor, 2023, p. 2)

How? #ⓘ

Retrospective cohort with propensity-score matching; continuous distributions compared between the interpreter-needed vs not-needed groups using the Wilcoxon rank-sum test.

"Wilcoxon rank-sum test was used to compare location parameters of continuous distributions between patient groups." (Kapoor, 2023, p. 2)

Who? #ⓘ

The propensity-matched cohort of 590 adults (295 per group) undergoing open abdominal oncologic surgery at a single academic cancer center, 2016–2021.

"After matching, a total of 590 patients (n = 295 per group) were included in the analysis." (Kapoor, 2023, p. 5)

Other Notes #

MEDD = Morphine Equivalent Daily Dose (Table 2 footnote). Note that total perioperative opioid did NOT differ significantly (33 vs 30 MEDD, p = 0.099; see separate EVD) — the significant reduction was specific to PACU opioid.

Caveats #

• Statistically significant pain and opioid differences were likely not clinically significant The statistically significant differences in pain intensity (and the corresponding opioid difference) were very small — under 1 unit on the 0–10 scale — and, by the authors' own assessment, may not be clinically significant. A significant p-value here reflects the large sample rather than a meaningful clinical effect, so the lower pain scores in LAS-needing patients should not be over-interpreted as a clinically important benefit.
• Retrospective single-institution cancer-center study with residual confounding The study is retrospective and conducted at a single cancer center, so its estimates are vulnerable to residual confounding from unmeasured variables that could have influenced opioid-prescribing and pain outcomes, and its findings are tied to institution-specific practices (types of surgeries and regional anesthesia techniques). Although propensity-score matching reduced measured baseline imbalance, no prior sample-size analysis was performed and unknown confounders remain. This limits causal interpretation and external generalizability of the pain, opioid, and regional-anesthesia associations.
• Actual mode and use of interpreters could not be determined; LAS need is a proxy The exposure is the need for language assistance services (recorded when a patient asked for an interpreter at their first encounter), not verified interpreter utilization. The actual use and mode of interpretation — phone, videoconferencing, or in-person — could not be retrospectively determined. Because interpreter modality and whether an interpreter was actually deployed at the point of pain assessment are unknown, the observed pain and opioid differences cannot be attributed to any specific form or dose of language assistance.